Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2024-11-14
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
Options: 2 call positions ($98.4m notional), 0 put positions (— notional) – listed below, not included above.
Holdings, Q3 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| NUVALENT INC COM | $511.5m17.90% | Added +428.3k |
| ARCELLX INC ACLX | $334.0m11.69% | Added +151.9k |
| ARGENX SE ARGX | $260.4m9.11% | Reduced -57.8k |
| REVOLUTION MEDICINES INC RVMD | $241.0m8.43% | Added +55.0k |
| CRINETICS PHARMACEUTICALS IN CRNX | $128.6m4.50% | Added +3.4k |
| MERUS N V MRUS | $122.6m4.29% | Added +435.1k |
| JANUX THERAPEUTICS INC JANX | $109.1m3.82% | Added +836.1k |
| KURA ONCOLOGY INC KURA | $84.6m2.96% | Reduced -208.1k |
| TARSUS PHARMACEUTICALS INC TARS | $80.3m2.81% | Added +5.0k |
| EDGEWISE THERAPEUTICS INC EWTX | $74.4m2.61% | Added +463.7k |
| DISC MEDICINE INC IRON | $73.6m2.58% | Reduced -1.2m |
| VAXCYTE INC PCVX | $71.7m2.51% | Added +530 |
| VIRIDIAN THERAPEUTICS INC VRDN | $65.9m2.31% | Reduced -660 |
| OLEMA PHARMACEUTICALS INC OLMA | $65.7m2.30% | Reduced -2.4m |
| ARVINAS INC ARVN | $57.6m2.02% | Reduced -98.2k |
| Y-MABS THERAPEUTICS INC YMAB | $53.7m1.88% | Added +215.8k |
| COGENT BIOSCIENCES INC COGT | $49.8m1.74% | Added +985.4k |
| VERA THERAPEUTICS INC VERA | $48.5m1.70% | New |
| MOONLAKE IMMUNOTHERAPEUTICS MLTX | $47.0m1.64% | New |
| BEIGENE LTD ONC | $45.0m1.57% | New |
| IMMATICS N.V IMTX | $44.6m1.56% | Added +482.9k |
| APOGEE THERAPEUTICS INC COM | $41.2m1.44% | Added +371.8k |
| IMMUNOVANT INC IMVT | $38.9m1.36% | Unchanged |
| CULLINAN THERAPEUTICS INC CGEM | $38.9m1.36% | Added +778.2k |
| SPYRE THERAPEUTICS INC SYRE | $37.3m1.30% | New |
| PLIANT THERAPEUTICS INC PLRX | $34.8m1.22% | New |
| KEROS THERAPEUTICS INC KROS | $30.5m1.07% | New |
| ERASCA INC ERAS | $29.1m1.02% | Added +3.4m |
| ORUKA THERAPEUTICS INC ORKA | $17.6m0.62% | New |
| PERSPECTIVE THERAPEUTICS INC CATX | $12.3m0.43% | Unchanged |
| COMPASS PATHWAYS PLC CMPS | $7.3m0.26% | Reduced -1.2m |
Sold out since Q2 2024
| Security | Value then |
|---|---|
| SAREPTA THERAPEUTICS INC SRPT | $149.7m947.6k shares |
| CEREVEL THERAPEUTICS HLDNG I CERE | $95.3m2.3m shares |
| ASCENDIS PHARMA A/S | $90.6m664.3k shares |
| XENON PHARMACEUTICALS INC XENE | $79.7m2.0m shares |
| LEGEND BIOTECH CORP LEGN | $53.3m1.2m shares |
| BRIDGEBIO PHARMA INC BBIO | $27.6m1.1m shares |
| VERONA PHARMA PLC VRNA | $10.4m721.1k shares |
| ALX ONCOLOGY HLDGS INC ALXO | $9.5m1.6m shares |
| VOR BIOPHARMA INC | $6.5m6.5m shares |
| ACRIVON THERAPEUTICS INC ACRV | $3.8m659.7k shares |
| TSCAN THERAPEUTICS INC TCRX | $2.1m353.9k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| ARCELLX INC ACLX · Call | $66.8m800.0k shares | New |
| VAXCYTE INC PCVX · Call | $31.6m276.8k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |
Trades reported as a company insider in Q3 2024
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2024-08-01 | OLEMA PHARMACEUTICALS INC 10% owner · By: Paradigm BioCapital International Fund Ltd. | Sold | $27.9m1.9m shares |
| 2024-08-01 | OLEMA PHARMACEUTICALS INC 10% owner · By: One or more separately managed accounts | Sold | $7.9m529.5k shares |